/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/ppo/,

/clinical/cckm-tools/content/ppo/name-99100-en.cckm

201608217

page

100

UWHC,UWMF,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Preprinted Paper Orders

GU Enzalutamide(28D:1-28) (4869 VER: 10-14-14)

GU Enzalutamide(28D:1-28) (4869 VER: 10-14-14) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Preprinted Paper Orders


Final Approved VER: 02-16-16 (4869 VER: 10-14-14) Page 1 of 2
Copyright © 2016 University of Wisconsin Hospitals and Clinics Authority Contact: CCKM@uwhealth.org
Title: Enzalutamide
Disease Group: Genitourinary
Disease: Prostate Cancer (Advanced)

Therapy: enzalutamide 160 mg by mouth continuously

Cycle Length: 28 days Course: until disease progression

Note to all Staff:
Dosage adjustment is needed for concomitant use with strong CYP2C8 inhibitors (for example, gemfibrozil).
Avoid concomitant use if possible. If coadministration is necessary, reduce enzalutamide dose to 80 mg once
daily. If the strong CYP2C8 inhibitor is discontinued, adjust the enzalutamide dose back up to the dose used
prior to the initiation of the inhibitor.

Patients with history of seizures may be at increased risk for seizures with this medication.

Reference(s): Scher HI, et al. N Engl J Med 2012;367(13):1187-97.

Allergies:  NKDA  Other ____________________________

Height _________cm Weight __________kg BSA ________m
2


Cycle _______ Starting with:  Day 1 (date) ___________

Pre labs:
• Cycle 1, Day 1: Obtain CBC with DIFF, Alkaline Phosphatase, PSA, Electrolytes, Glucose, BUN, Creatinine,
Calcium, ALT, Total Bilirubin
 Other:


• Cycle 2+, Day 1: Obtain CBC with DIFF, Alkaline Phosphatase, PSA, LDH, Creatinine, Calcium, Albumin, ALT,
Total Bilirubin (every 3
rd
cycle).
 Other:


Treatment Conditions:
• Verify Informed consent obtained Day 1 of each cycle.
• Verify the following labs have been obtained:
 Day 1 (every cycle): Creatinine
 Day 1 (every 3
rd
cycle): Creatinine, Total Bilirubin
• Hold and notify provider for: Creatinine Clearance less than 30 mL/min

Nursing Procedure, Assessment and Monitoring: None

Hydration/Fluids: None

Premedications/Antiemetics: None

Treatment Medications for Day 1: See Take Home Medication Section

Final Approved VER: 02-16-16 (4869 VER: 10-14-14) Page 2 of 2
Copyright © 2016 University of Wisconsin Hospitals and Clinics Authority Contact: CCKM@uwhealth.org
Take Home Medications - (Prescribe Cycle 1, Day 1: Review for adequate supply during treatment)
• enzalutamide (Xtandi) 40 mg capsule, Disp. # _________, Refills: ______
Take _______ capsules (_______ mg) by mouth once daily.

 Other:





Follow Up
• Chemotherapy: Day 1 every 28 days

• Labs:
 Other:



• Procedures/Imaging/Scans:











• Other Orders:







MD Signature_________________________________________ Pager______________
Date __________________Time___________________


Order Verification:
RN Signature: __________________________ Date: ___________ Time: __________ Pager #: ________
RPh Signature: _________________________ Date: ___________ Time: __________ Pager #: ________